TrialsgrambetaRCTs are beautiful

2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope

This guideline cites 4 of the 199 landmark trials in our Cardiology register.

The first US guideline dedicated to syncope, published a year before the ESC's. Its most useful contribution is negative: in a patient with syncope and no focal neurological findings, routine head CT or MRI, carotid ultrasound and EEG are Class 3 (no benefit) — testing that is still ordered in a large minority of patients. Everything else follows a structured history, examination and ECG, with risk stratification driving disposition from the emergency department. On treatment the two societies broadly agree — physical counterpressure manoeuvres first, drugs only for a heavy symptom burden, and pacing reserved for documented spontaneous asystole in older patients with recurrent reflex syncope. The register's trials are grouped below.

Pharmacotherapy of reflex syncope2

  • 2016POST-2⁠Cardiology · Arrhythmia · Vasovagal syncopeIn 210 patients with recurrent vasovagal syncope, fludrocortisone did not significantly reduce the first recurrence of syncope over one year compared with placebo, although a benefit emerged once the dose had been stabilised.HR 0.6995% CI 0.46-1.03Read →
  • 2006POST⁠Cardiology · Arrhythmia · Vasovagal syncopeIn 208 patients with recurrent vasovagal syncope and a positive tilt test, metoprolol at the highest tolerated dose did not reduce the first recurrence of syncope over one year compared with placebo.HR 0.8995% CI 0.63-1.25Read →

Pacing: only for documented asystole2

  • 2012ISSUE-3⁠Cardiology · Arrhythmia · Pacing for reflex syncopeIn 77 patients aged 40 years or older with recurrent reflex syncope and asystole documented by an implantable loop recorder, an active dual-chamber pacemaker reduced recurrence of syncope at 2 years compared with the same pacemaker programmed to sensing only.25% vs 57%Read →
  • 2003VPS-II⁠Cardiology · Arrhythmia · Pacing for reflex syncopeIn 100 patients with recurrent severe vasovagal syncope who all received a dual-chamber pacemaker, active dual-chamber pacing did not significantly reduce recurrence of syncope within 6 months compared with the pacemaker programmed to sensing only.31% vs 40%Read →

Published since the guideline2

  • 2021POST-4⁠Cardiology · Arrhythmia · Vasovagal syncopeIn 133 patients with recurrent vasovagal syncope and no serious comorbidity, midodrine reduced the proportion of patients with at least one syncope episode over 12 months compared with placebo.RR 0.6995% CI 0.49-0.97Read →
  • 2021BIOSync CLS⁠Cardiology · Arrhythmia · Pacing for reflex syncopeIn 127 patients aged 40 years or older with severe recurrent reflex syncope and tilt-induced asystole, a dual-chamber pacemaker with closed-loop stimulation reduced recurrence of syncope compared with the same pacemaker programmed off.HR 0.2395% CI 0.11-0.47Read →

Cited landmark trials not yet in the register4

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 1999VPS-I

    The unblinded pacing trial whose apparent benefit VPS-II later exposed as a placebo effect of surgery.

  • 2004SYNPACE

    Pacing vs. sensing-only in tilt-positive syncope — neutral.

  • 2006PC-Trial

    Physical counterpressure manoeuvres reduce syncope recurrence.

  • 2006ISSUE-2

    The loop-recorder study that generated the mechanism-guided pacing hypothesis.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.